Compare AbbVie Inc (ABBV) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs GoPro Inc — how do they compare? AbbVie Inc trades at $247.73 (market cap $441.94B), while GoPro Inc trades at $0.62 (market cap $114.41M). The key difference: AbbVie Inc is far larger — about 3862.8× GoPro Inc's market cap, and AbbVie Inc pays a 2.77% dividend while GoPro Inc pays none. Which is the better fit depends on your goals.
| ABBV | GPRO | |
|---|---|---|
Market Cap | $441.94B | $114.41M |
Sector | Health | Technology |
52-Week High | $263.58 | $2.88 |
52-Week Low | $197.38 | $0.62 |
Enterprise Value | $506.19B | $173.19M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
GoPro (GPRO) trades at $0.70, down 3.53% in the last 24 hours, reflecting ongoing financial distress with a net income margin of -28.52% and negative cash flow. The stock is technically bearish, with moving averages signaling sell pressure, while recent news highlights a strategic review for a potential sale. Revenue has declined from $1.1B in 2022 to $652M in 2025, with consistent earnings misses and negative equity of -$681.61M.
The outlook hinges on the outcome of the strategic sale process, offering speculative upside if a buyer emerges, but risks include persistent cash burn, competitive pressures, and weak sales trends. Analysts are cautious, with only 21.43% recommending buy, as the company faces going-concern risks and dilution from financing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
